These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 4678592)

  • 1. Phenobarbital effects on cyclophosphamide pharmacokinetics in man.
    Jao JY; Jusko WJ; Cohen JL
    Cancer Res; 1972 Dec; 32(12):2761-4. PubMed ID: 4678592
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of phenobarbital and SKF 525A on placental transfer of cyclophosphamide in mice.
    Gibson JE; Becker BA
    J Pharmacol Exp Ther; 1971 Apr; 177(1):256-62. PubMed ID: 5566767
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of phenobarbital and SKF 525A on the toxicity, elimination and metabolism of cyclophosphamide in newborn mice.
    Bus JS; Short RD; Gibson JE
    J Pharmacol Exp Ther; 1973 Mar; 184(3):749-56. PubMed ID: 4687235
    [No Abstract]   [Full Text] [Related]  

  • 4. Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo.
    Sladek NE
    Cancer Res; 1973 Jun; 33(6):1150-8. PubMed ID: 4718666
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics of cyclophosphamide in man.
    Cohen JL; Jao JY; Jusko WJ
    Br J Pharmacol; 1971 Nov; 43(3):677-80. PubMed ID: 5157730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology of cyclophosphamide.
    Bagley CM; Bostick FW; DeVita VT
    Cancer Res; 1973 Feb; 33(2):226-33. PubMed ID: 4688880
    [No Abstract]   [Full Text] [Related]  

  • 7. Metabolism of anticancer agents in man.
    Adamson RH
    Ann N Y Acad Sci; 1971 Jul; 179():432-41. PubMed ID: 4936777
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of phenobarbital or 2-diethylaminoethyl-2,2-diphenylvalerate on the activation of cyclophosphamide in vivo.
    Field RB; Gang M; Kline I; Venditti JM; Waravdekar VS
    J Pharmacol Exp Ther; 1972 Feb; 180(2):475-83. PubMed ID: 5010684
    [No Abstract]   [Full Text] [Related]  

  • 9. The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects.
    Mouridsen HT; Faber O; Skovsted L
    Acta Pharmacol Toxicol (Copenh); 1974 Aug; 35(2):98-106. PubMed ID: 4479366
    [No Abstract]   [Full Text] [Related]  

  • 10. Enzymatic metabolism of cyclophosphamide and nicotine and production of a toxic cyclophosphamide metabolite.
    Hill DL; Laster WR; Struck RF
    Cancer Res; 1972 Apr; 32(4):658-65. PubMed ID: 5014778
    [No Abstract]   [Full Text] [Related]  

  • 11. Modification of the mutagenicity and teratogenicity of cyclophosphamide in rats with inducers of the cytochromes P-450.
    Hales BF
    Teratology; 1981 Aug; 24(1):1-11. PubMed ID: 7029774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of phenobarbital on cyclophosphamide cytotoxic activity and pharmacokinetics in mice.
    Donelli MG; Vecchi A; Bossi A; Colombo T; Sironi M; Pantarotto C; Garattini S; Spreafico F
    Tumori; 1977; 63(2):137-46. PubMed ID: 898284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose cyclophosphamide versus cyclophosphamide, methotrexate, 5-FU, and hydroxyurea (CMFH) in the treatment of stage III non-small cell bronchogenic carcinoma: a randomized trial.
    Pannuti F; Lelli G; Casadio M; Piana E; Di Marco AR
    Cancer Treat Rep; 1980; 64(10-11):1131-4. PubMed ID: 7459899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Competitive inhibition of the metabolism of 2(bis-(2-chlorethyl)-amino)-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide by phenylbutazone and phenobarbital in the rat].
    Norpoth K; Lukasiewicz G; Philipp J; Rauen HM
    Arzneimittelforschung; 1970 Dec; 20(12):1879-81. PubMed ID: 5537087
    [No Abstract]   [Full Text] [Related]  

  • 15. WR-2721: enhanced chemoprotection by increasing cyclophosphamide activation with phenobarbitol.
    Glover DJ; Yuhas JM; Glick JH
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):571-4. PubMed ID: 6286555
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II study of cyclophosphamide and hexamethylmelamine in non-oat cell bronchogenic carcinoma.
    Pisoni MB; Libretti A; Piazza E; Vago G; Scapaticci R; Bianchi C; Tomirotti M; Scanni A; Calzavara MP; Cassani L; Scarpazza G; Marsoni S; Morasca L
    Cancer Treat Rep; 1981; 65(7-8):731-2. PubMed ID: 6788372
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug oxidation.
    Nature; 1970 Jul; 227(5253):16. PubMed ID: 5422617
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of cyclophosphamide (Endoxan) in advanced inoperable bronchogenic carcinoma.
    Guleria JS; Malik SK
    Indian J Chest Dis; 1967 Jul; 9(3):135-8. PubMed ID: 5634276
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic efficacy of cyclophosphamide as a function of its metabolism.
    Sladek NE
    Cancer Res; 1972 Mar; 32(3):535-42. PubMed ID: 5061308
    [No Abstract]   [Full Text] [Related]  

  • 20. The biotransformation of cyclophosphamide in man: influence of prednisone.
    Faber OK; Mouridsen HT; Skovsted L
    Acta Pharmacol Toxicol (Copenh); 1974 Sep; 35(3):195-200. PubMed ID: 4479295
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.